Everything seemed to be aligned for success, but shares in leading Chinese antibody developer RemeGen recently dropped by nearly 40%, reflecting a range of internal and external likely factors.

In this week's podcast edition of Five Must-Know Things: J&J’s Spravato on track for blockbuster status; US uptake of Rezzdifra held up by payers; CNS drugs are surprisingly valuable; obesity rules large cap stocks; and Legend buyout rumors validate China biotech. 

After acquiring a majority stake in ProteoVant last year, South Korea's SK Biopharm is continuing to hunt for new modalities and is now moving into the hot radiotherapeutics area through a deal with Full-Life Technologies.

A reported buyout bid for Legend Biotech has delivered a much needed shot of confidence to the Chinese biotech sector, despite not being confirmed. Amid a shifting environment, Hengrui also sees globalization as essential to its future.